RECRUITINGOBSERVATIONAL
Hormonal, Metabolic, and Signaling Interactions in PAH
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
About This Trial
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Who May Be Eligible (Plain English)
Who May Qualify:
Project 1
Inclusion:
1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
2. Age 0-90, age 12-90 for skin biopsy
Exclusion:
1. Other diagnosis
2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy
Project 2
Inclusion:
1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 0-90
3. Subjects with reasonably easy access to clinic for blood collection and other testing
4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
Exclusion:
1. Other diagnosis
2. 0-90
3. Subjects with difficulty reaching clinic for blood collection and other testing
4. Subjects unable to tolerate fasting state
Project 3
Inclusion:
1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 7-90
Exclusion:
1. Other diagnosis
2. Age less than 7 or greater than 90
\-
Who Should NOT Join This Trial:
\-
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Project 1
Inclusion:
1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
2. Age 0-90, age 12-90 for skin biopsy
Exclusion:
1. Other diagnosis
2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy
Project 2
Inclusion:
1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 0-90
3. Subjects with reasonably easy access to clinic for blood collection and other testing
4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
Exclusion:
1. Other diagnosis
2. 0-90
3. Subjects with difficulty reaching clinic for blood collection and other testing
4. Subjects unable to tolerate fasting state
Project 3
Inclusion:
1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 7-90
Exclusion:
1. Other diagnosis
2. Age less than 7 or greater than 90
\-
Exclusion Criteria:
\-
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States